Table 1 Study sample characteristics
Reference group n = 1402 | Arterial Disease group n = 502 | Venous Disease group n = 195 | |
|---|---|---|---|
Sex (females) | 60.5% (848) | 36.7% (184) | 63.6% (124) |
Age(years) | 49.3 ± 9.8 | 63.8 ± 8.5 | 61.3 ± 10.1 |
BMI (kg/m2) | 24.2 (22.2/26.3) | 28.8 (25.7/32.2) | 28.6 (25.5/31.5) |
Cardiovascular risk factors | |||
Diabetes | 0% (0) | 20.1% (101) | 9.7% (19) |
Obesity | 0% (0) | 41.2% (207) | 36.9% (72) |
Smoking | 22.5% (316) | 16.2% (81) | 11.3% (22) |
Arterial hypertension | 0% (0) | 72.5% (364) | 59.0% (115) |
Dyslipidemia | 0% (0) | 40.1% (201) | 30.8% (60) |
Family history of MI/Stroke | 31.1% (436) | 43.6% (219) | 43.6% (85) |
Comorbidities | |||
CAD | 0% (0) | 46.5% (217) | 9.1% (17) |
MI | 0% (0) | 30.4% (151) | 5.2% (10) |
Stroke | 0% (0) | 18.5% (92) | 6.2% (12) |
AF | 0% (0) | 9.2% (45) | 6.2% (12) |
PAD | 0% (0) | 40.2% (200) | 26.6% (51) |
CHF | 0% (0) | 6.2% (31) | 6.7% (13) |
DVT | 0% (0) | 14.3% (71) | 99.0% (193) |
PE | 0% (0) | 1.6% (8) | 5.7% (11) |
Therapy | |||
Anti-coagulant agentsa | 1.8% (25) | 61.0% (305) | 35.4% (69) |
Oral contraceptive therapy | 12.5% (174) | 6.4% (32) | 9.7% (19) |
Hormonal replacement therapy | 5.5% (77) | 5.6% (28) | 11.3% (22) |